Biology Reference
In-Depth Information
159. Burger D, Lei M, Geoghegan-Morphet N, Lu
X, Xenocostas A, Feng Q (2006) Erythropoietin
protects cardiomyocytes from apoptosis via up-
regulation of endothelial nitric oxide synthase.
Cardiovasc Res 72:51-59
160. Fliser D, Bahlmann FH, deGroot K, Haller H
(2006) Mechanisms of disease: erythropoie-
tin—an old hormone with a new mission? Nat
Clin Pract Cardiovasc Med 3:563-572
161. Vogiatzi G, Briasoulis A, Tousoulis D,
Papageorgiou N, Stefanadis C (2010) Is there
a role for erythropoietin in cardiovascular dis-
ease? Expert Opin Biol Ther 10:251-264
162. Burger D, Xenocostas A, Feng QP (2009)
Molecular basis of cardioprotection by eryth-
ropoietin. Curr Mol Pharmacol 2:56-69
163. Mihov D, Vogel J, Gassmann M, Bogdanova
A (2009) Erythropoietin activates nitric oxide
synthase in murine erythrocytes. Am J Physiol
Cell Physiol 297:C378-C388
164. Li H, Wallerath T, Munzel T, Forstermann U
(2002) Regulation of endothelial-type NO
synthase expression in pathophysiology and in
response to drugs. Nitric Oxide 7:149-164
165. Ziolo MT, Kohr MJ, Wang H (2008) Nitric
oxide signaling and the regulation of myocar-
dial function. J Mol Cell Cardiol 45:625-632
166. Joyeux-Faure M, Ramond A, Beguin PC,
Belaidi E, Godin-Ribuot D, Ribuot C (2006)
Early pharmacological preconditioning by
erythropoietin mediated by inducible NOS
and mitochondrial ATP-dependent potassium
channels in the rat heart. Fundam Clin
Pharmacol 20:51-56
167. Baker JE, Kozik D, Hsu AK, Fu X, Tweddell
JS, Gross GJ (2007) Darbepoetin alfa pro-
tects the rat heart against infarction: dose-
response, phase of action, and mechanisms.
J Cardiovasc Pharmacol 49:337-345
168. Carraway MS, Suliman HB, Jones WS, Chen
CW, Babiker A, Piantadosi CA (2010)
Erythropoietin activates mitochondrial bio-
genesis and couples red cell mass to mito-
chondrial mass in the heart. Circ Res
106:1722-1730
169. Cook SA, Matsui T, Li L, Rosenzweig A
(2002) Transcriptional effects of chronic Akt
activation in the heart. J Biol Chem
277:22528-22533
170. Krishnan J, Suter M, Windak R, Krebs T, Felley
A, Montessuit C, Tokarska-Schlattner M,
Aasum E, Bogdanova A, Perriard E, Perriard
JC, Larsen T, Pedrazzini T, Krek W (2009)
Activation of a HIF1alpha-PPARgamma axis
underlies the integration of glycolytic and lipid
anabolic pathways in pathologic cardiac hyper-
trophy. Cell Metab 9:512-524
171. Matsui T, Tao J, del Monte F, Lee KH, Li L,
Picard M, Force TL, Franke TF, Hajjar RJ,
Rosenzweig A (2001) Akt activation preserves
cardiac function and prevents injury after
transient cardiac ischemia in vivo. Circulation
104:330-335
172. Gross AW, Lodish HF (2006) Cellular
trafficking and degradation of erythropoietin
and novel erythropoiesis stimulating protein
(NESP). J Biol Chem 281:2024-2032
173. Moon C, Krawczyk M, Paik D, Lakatta EG,
Talan MI (2005) Cardioprotection by recom-
binant human erythropoietin following acute
experimental myocardial infarction: dose
response and therapeutic window. Cardiovasc
Drugs Ther 19:243-250
174. Jelkmann W, Wagner K (2004) Beneficial and
ominous aspects of the pleiotropic action of
erythropoietin. Ann Hematol 83:673-686
175. Andreotti F, Agati L, Conti E, Santucci E,
Rio T, Tarantino F, Natale L, Berardi D,
Mattatelli A, Musumeci B, Bonomo L, Volpe
M, Crea F, Autore C (2009) Update on phase
II studies of erythropoietin in acute myocar-
dial infarction. Rationale and design of
Exogenous erythroPoietin in Acute
Myocardial Infarction: New Outlook aNd
Dose Association Study (EPAMINONDAS).
J Thromb Thrombolysis 28:489-495
176. Kang HJ, Kim HS (2008) G-CSF- and eryth-
ropoietin-based cell therapy: a promising
strategy for angiomyogenesis in myocardial
infarction. Expert Rev Cardiovasc Ther
6:703-713
177. McMurray JJ, Uno H, Jarolim P, Desai AS,
de Zeeuw D, Eckardt KU, Ivanovich P,
Levey AS, Lewis EF, McGill JB, Parfrey P,
Parving HH, Toto RM, Solomon SD, Pfeffer
MA (2011) Predictors of fatal and nonfatal
cardiovascular events in patients with type 2
diabetes mellitus, chronic kidney disease,
and anemia: an analysis of the Trial to
Reduce cardiovascular Events with Aranesp
(darbepoetin-alfa) Therapy (TREAT). Am
Heart J 162(748-755):e743
178. Joyeux-Faure M, Durand M, Bedague D,
Protar D, Incagnoli P, Paris A, Ribuot C,
Levy P, Chavanon O (2011) Evaluation of
the effect of one large dose of erythropoie-
tin against cardiac and cerebral ischemic
injury occurring during cardiac surgery with
cardiopulmonary bypass: a randomized
double-blind placebo-controlled pilot study.
Fundam Clin Pharmacol 26:761-770
179. van der Meer P, van Veldhuisen DJ (2011)
Acute coronary syndromes: the unfulfilled
promise of erythropoietin in patients with
MI. Nat Rev Cardiol 8:425-426
Search WWH ::
Custom Search